The March 2026 quarter marks a critical inflection point for Riddhi Siddhi Gluco Biols, with revenue collapsing to a multi-quarter low of ₹9.05 crores—a precipitous 77.42% decline from the previous quarter's ₹40.08 crores and 67.70% down year-on-year. This dramatic revenue contraction, coupled with ballooning operating losses, has pushed the company into deeply negative territory. With promoter holdings increasing to 86.55% in March 2026 from 74.54% in prior quarters, management appears to be demonstrating confidence, yet operational metrics paint a picture of severe distress that cannot be ignored.
| Quarter | Net Sales (₹ Cr) | QoQ Change | YoY Change | Net Profit (₹ Cr) | Operating Margin % |
|---|---|---|---|---|---|
| Mar'26 | 9.05 | -77.42% | -67.70% | -32.54 | -89.06% |
| Dec'25 | 40.08 | +24.86% | -9.59% | -1.59 | -13.80% |
| Sep'25 | 32.10 | -79.24% | -34.36% | 13.54 | 4.83% |
| Jun'25 | 154.61 | +451.78% | — | 8.28 | -0.17% |
| Mar'25 | 28.02 | -36.79% | — | 3.63 | -12.28% |
| Dec'24 | 44.33 | -9.35% | — | -36.05 | -1.69% |
| Sep'24 | 48.90 | — | — | 13.50 | 13.11% |
Financial Performance: A Quarter of Severe Deterioration
The March 2026 quarter witnessed a catastrophic collapse in Riddhi Siddhi Gluco Biols' operational performance. Net sales plummeted to ₹9.05 crores, down 77.42% sequentially from ₹40.08 crores in December 2025 and 67.70% lower year-on-year from ₹28.02 crores. This represents the lowest quarterly revenue recorded in the available data set, signalling acute business disruption. The company's operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI) turned sharply negative at ₹-8.06 crores, yielding an operating margin of -89.06%—the worst performance across all tracked quarters.
On a standalone basis, the company reported a net loss of ₹4.94 crores in Q4 FY26 compared to a profit of ₹2.65 crores in Q4 FY25, while the consolidated loss ballooned to ₹32.54 crores from a profit of ₹3.63 crores year-on-year. The sequential deterioration was equally stark, with consolidated losses surging 1,946.54% from ₹-1.59 crores in the previous quarter. Interest costs climbed to ₹4.49 crores from ₹2.56 crores a year earlier—a 75.39% increase—further straining profitability. The company's profit before tax turned negative at ₹-3.58 crores despite other income contributing ₹11.00 crores, underscoring the severity of core operational challenges.
The gross profit margin also deteriorated sharply to -17.13% in Q4 FY26 from 71.88% in the year-ago quarter, indicating severe pricing pressure or cost overruns. Employee costs remained relatively stable at ₹2.08 crores, but as a percentage of revenue, they ballooned to 22.98% from 7.35% a year earlier, highlighting the revenue crisis. The PAT margin collapsed to -54.59% from 9.46%, reflecting the comprehensive breakdown in profitability across all operational layers.
⚠️ Critical Operational Warning
Revenue Collapse: Net sales fell to a multi-quarter low of ₹9.05 crores, down 77.42% quarter-on-quarter and 67.70% year-on-year. Operating losses at ₹-8.06 crores and an operating margin of -89.06% signal fundamental business distress. The operating profit to interest coverage ratio plunged to -1.80 times, the lowest on record, raising serious solvency concerns.
Return on Equity: Weak Capital Efficiency Persists
Riddhi Siddhi Gluco Biols continues to exhibit weak capital efficiency, with the latest return on equity (ROE) standing at 4.10%—marginally above the five-year average of 2.59% but far below industry standards for healthy companies. Higher ROE indicates better capital efficiency and profitability, and the company's persistent underperformance on this metric reflects structural challenges in generating adequate returns for shareholders. The average return on capital employed (ROCE) over the past five years has been negative at -1.13%, further underscoring the company's inability to deploy capital productively.
The balance sheet reveals shareholder funds of ₹1,549.09 crores as of March 2025, with negligible long-term debt (₹0.71 crores in March 2024, reduced to zero by March 2025), suggesting low financial leverage. However, the company's net debt to equity ratio of 0.14 and debt to EBITDA of 16.14 times (on average) indicate that even modest debt levels have been challenging to service given weak operational cash generation. Current liabilities stood at ₹182.09 crores, up from ₹167.68 crores in the previous year, with trade payables at ₹7.58 crores and other current liabilities at ₹73.54 crores.
Balance Sheet Snapshot: Limited Leverage, Weak Returns
As of March 2025, Riddhi Siddhi Gluco Biols maintained shareholder funds of ₹1,549.09 crores with virtually no long-term debt, suggesting conservative financial management. However, fixed assets stood at ₹432.86 crores, investments at ₹306.54 crores, and current assets at ₹610.24 crores. Despite this asset base, the company's average ROCE of -1.13% and ROE of 2.59% highlight persistent inefficiencies in capital deployment. The company's average EBIT to interest coverage of -1.04 times signals that operating profits have consistently failed to cover interest obligations, a red flag for financial sustainability.
Cash Flow Challenges: Negative Operating Cash Generation
The cash flow statement for FY25 reveals troubling trends. Cash flow from operations turned negative at ₹-28.00 crores, down from a positive ₹8.00 crores in FY24, driven by a profit before tax of ₹-12.00 crores and adverse working capital changes of ₹-23.00 crores. While cash flow from investing activities contributed ₹20.00 crores (likely from asset sales or divestments), and financing activities added ₹7.00 crores, the net cash inflow for the year was zero, with closing cash remaining flat at ₹0.00 crores. This suggests the company is consuming cash at the operational level and relying on non-operating sources to maintain liquidity—a pattern that is unsustainable over the long term.
Peer Comparison: Valuation Disconnect Amidst Weak Fundamentals
When benchmarked against peers in the trading and distribution sector, Riddhi Siddhi Gluco Biols presents a mixed valuation picture. The company trades at a price-to-earnings (P/E) ratio of 19.22 times, below the peer average of approximately 61 times, and a price-to-book (P/BV) ratio of 0.32 times, significantly lower than the peer average of around 2.9 times. However, the company's ROE of 2.59% lags behind peers such as Yamuna Syndicate (8.57%) and SMT Engineering (7.25%), justifying the valuation discount.
| Company | P/E (TTM) | P/BV | ROE % | Debt to Equity | Dividend Yield |
|---|---|---|---|---|---|
| Riddhi Siddhi Gluco Biols | 19.22 | 0.32 | 2.59% | 0.14 | 0.42% |
| Yamuna Syndicate | 8.20 | 0.70 | 8.57% | -0.02 | — |
| SMT Engineering | 53.47 | 9.83 | 7.25% | 0.84 | — |
| S T C | 15.67 | -0.18 | 0.00% | -0.30 | — |
| Polo Queen Ind. | 222.46 | 3.31 | 1.22% | 0.05 | — |
| Oswal Agro Mills | 7.09 | 0.64 | 4.14% | -0.18 | — |
The low P/BV of 0.32 times suggests the market is pricing Riddhi Siddhi Gluco Biols at a steep discount to its book value of ₹2,172.72 per share, reflecting scepticism about the company's ability to generate sustainable returns. The dividend yield of 0.42% (based on a latest dividend of ₹3.00 per share) is modest, and the negative dividend payout ratio of -17.58% indicates the company paid dividends despite losses—a concerning practice that raises questions about capital allocation discipline.
Valuation Analysis: Risky Territory Despite Low Multiples
Riddhi Siddhi Gluco Biols' valuation metrics present a paradox. On one hand, the P/E ratio of 19.22 times and P/BV of 0.32 times appear attractive relative to historical norms and peer averages. On the other hand, negative enterprise value multiples—EV/EBITDA of -95.35 times and EV/EBIT of -45.74 times—reflect the company's operational losses and deteriorating fundamentals. The EV/Sales ratio of 2.87 times suggests the market is still ascribing some value to the revenue base, but this is overshadowed by the absence of profitability.
The stock's valuation grade has been classified as "Risky" since October 2020, with the company cycling through "Very Expensive" and "Expensive" ratings prior to that. This reflects persistent concerns about overvaluation relative to underlying earnings power. With the stock trading at ₹699.80 as of May 25, 2026—14.23% below its 52-week high of ₹815.90 but 72.79% above its 52-week low of ₹405.00—investors appear to be betting on a turnaround that has yet to materialise. The current market capitalisation of ₹483.00 crores values the company at approximately 3.58 times its FY25 net sales of ₹135.00 crores, a premium that seems unjustified given the negative earnings trajectory.
Shareholding Pattern: Promoter Confidence Amid Retail Exodus
The shareholding pattern reveals a significant shift in March 2026, with promoter holdings surging to 86.55% from 74.54% in the previous three quarters—a substantial increase of 12.01 percentage points. This increase was mirrored by a corresponding decline in non-institutional holdings, which fell to 13.44% from 25.45%. The key promoter entities include Creelotex Engineers Private Limited (50.75%), Ganpatraj Lalchand Chowdhary (17.92%), Vita Connections LLP (12.01%), Rajuldevi G Chowdhary (5.59%), and Siddharth G Chowdhary (0.28%).
| Quarter | Promoter % | QoQ Change | FII % | MF % | Non-Institutional % |
|---|---|---|---|---|---|
| Mar'26 | 86.55% | +12.01% | 0.00% | 0.01% | 13.44% |
| Dec'25 | 74.54% | 0.00% | 0.00% | 0.01% | 25.45% |
| Sep'25 | 74.54% | 0.00% | 0.00% | 0.01% | 25.45% |
| Jun'25 | 74.54% | 0.00% | 0.00% | 0.01% | 25.45% |
| Mar'25 | 74.54% | — | 0.00% | 0.01% | 25.45% |
The sharp increase in promoter holdings can be interpreted as a vote of confidence from insiders, potentially signalling their belief in a future turnaround. However, it also reflects the absence of institutional interest—FII and insurance holdings remain at zero, while mutual fund participation is negligible at 0.01%. The institutional holding of just 0.01% underscores the lack of professional investor confidence in the company's prospects. Positively, there is no promoter pledging, eliminating one potential risk factor.
Stock Performance: Technical Strength Masking Fundamental Weakness
Despite the dire fundamental picture, Riddhi Siddhi Gluco Biols' stock has delivered impressive returns across multiple timeframes. Over the past year, the stock has gained 21.28%, outperforming the Sensex, which fell 6.40%, resulting in an alpha of 27.68 percentage points. Year-to-date returns stand at a remarkable 66.56%, with the stock surging 76.81 percentage points ahead of the Sensex's -10.25% decline. Over three years, the stock has more than doubled, returning 101.88% compared to the Sensex's 23.62%, delivering an alpha of 78.26 percentage points.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Day | 3.39% | 1.42% | +1.97% |
| 1 Week | 4.00% | 1.56% | +2.44% |
| 1 Month | 18.86% | -0.23% | +19.09% |
| 3 Months | 45.79% | -7.03% | +52.82% |
| 6 Months | 43.53% | -9.57% | +53.10% |
| YTD | 66.56% | -10.25% | +76.81% |
| 1 Year | 21.28% | -6.40% | +27.68% |
| 2 Years | 17.69% | 1.43% | +16.26% |
| 3 Years | 101.88% | 23.62% | +78.26% |
| 5 Years | 85.89% | 51.05% | +34.84% |
The stock's risk-adjusted return over one year stands at 0.41, positive but modest, with volatility at an elevated 52.42%—classifying it as a high-risk, high-return investment. The stock's beta of 1.50 indicates it is 50% more volatile than the broader market, amplifying both gains and losses. Recent price action has been strong, with the stock trading above all key moving averages—5-day (₹683.66), 20-day (₹683.73), 50-day (₹564.10), 100-day (₹526.51), and 200-day (₹532.11)—suggesting sustained technical momentum.
The technical trend turned "Bullish" on May 13, 2026, at ₹698.20, shifting from "Mildly Bullish." Weekly and monthly MACD indicators remain bullish, as do Bollinger Bands, reinforcing the positive technical outlook. However, this technical strength stands in stark contrast to the deteriorating fundamentals, creating a dangerous disconnect. Delivery volumes have surged, with the one-month delivery change at 47.09% and one-day delivery at 477.15% versus the five-day average, indicating heightened retail participation—often a contrarian warning signal.
Investment Thesis: Negative Financial Trend Dominates
Riddhi Siddhi Gluco Biols' investment thesis is severely compromised by a "Negative" financial trend as of March 2026. The company's quarterly performance exhibited multiple red flags: net sales at a multi-quarter low of ₹9.05 crores, PBDIT at ₹-8.06 crores (the lowest recorded), operating profit to net sales at -89.06% (the worst margin), and operating profit to interest coverage at -1.80 times (the lowest). Earnings per share (EPS) for the quarter stood at ₹-45.64, reflecting the depth of the loss. While profit before tax less other income (PBT less OI) was at ₹13.21 crores—the highest in recent quarters—this was driven entirely by other income of ₹11.00 crores, masking core operational weakness.
The company's quality assessment is "Below Average," reflecting weak long-term financial performance. Five-year sales growth is negative at -9.03%, though five-year EBIT growth is positive at 11.63%. The average EBIT to interest coverage of -1.04 times and average debt to EBITDA of 16.14 times highlight chronic difficulties in servicing debt despite low absolute leverage. The average ROCE of -1.13% and ROE of 2.59% underscore persistent capital inefficiency. On the positive side, there is no promoter pledging, and the company maintains low net debt to equity of 0.14.
Key Strengths & Risk Factors
✅ KEY STRENGTHS
- Promoter Commitment: Promoter holdings increased to 86.55% in March 2026, demonstrating strong insider confidence and alignment with minority shareholders.
- Zero Promoter Pledging: No pledging of promoter shares eliminates a key governance risk and potential overhang on the stock.
- Low Financial Leverage: Net debt to equity of 0.14 and zero long-term debt as of March 2025 provide financial flexibility and reduce solvency risk.
- Strong Technical Momentum: Stock has delivered 66.56% YTD returns and trades above all key moving averages, with bullish MACD and Bollinger Bands.
- Substantial Asset Base: Fixed assets of ₹432.86 crores and investments of ₹306.54 crores as of March 2025 provide a tangible backing to shareholder funds.
⚠️ KEY CONCERNS
- Severe Revenue Collapse: Net sales plummeted to ₹9.05 crores in Q4 FY26, down 77.42% QoQ and 67.70% YoY, signalling acute business disruption.
- Massive Operating Losses: Operating margin of -89.06% and PBDIT of ₹-8.06 crores reflect fundamental operational breakdown.
- Weak Return Metrics: ROE of 4.10% and average ROCE of -1.13% highlight chronic capital inefficiency and poor profitability.
- Negative Financial Trend: Quarterly financial trend classified as "Negative" with multiple metrics at multi-quarter lows.
- Reliance on Other Income: Core operations unprofitable; other income of ₹11.00 crores in Q4 FY26 masked underlying weakness.
- Absence of Institutional Support: FII and insurance holdings at zero, mutual fund participation negligible at 0.01%, reflecting lack of professional investor confidence.
- Negative Cash Flow from Operations: FY25 operating cash flow at ₹-28.00 crores indicates the company is burning cash operationally.
Outlook: Critical Monitoring Points Ahead
📈 POSITIVE CATALYSTS
- Sustained revenue recovery above ₹40-50 crores per quarter
- Return to positive operating margins (PBDIT excluding OI)
- Improvement in ROE above 8-10% levels
- Entry of institutional investors (FIIs or mutual funds)
- Positive operating cash flow generation for consecutive quarters
🚨 RED FLAGS
- Further revenue decline below ₹10 crores per quarter
- Continued operating losses for more than two consecutive quarters
- Decline in promoter holdings from current 86.55% levels
- Increase in debt levels or deterioration in interest coverage
- Negative operating cash flow persisting beyond FY26
The coming quarters will be critical for Riddhi Siddhi Gluco Biols. Investors should closely monitor whether the company can stabilise revenue, return to positive operating margins, and generate sustainable cash flow from operations. The current technical rally, while impressive, lacks fundamental support and poses significant downside risk if operational metrics fail to improve. The company's "Below Average" quality grade, "Risky" valuation classification, and "Negative" financial trend collectively suggest that the stock is unsuitable for conservative investors seeking stable returns.
The Verdict: High Risk, Weak Fundamentals Warrant Exit
Score: 29/100
For Fresh Investors: Avoid initiating positions. The company faces severe operational challenges, with revenue collapsing to ₹9.05 crores in Q4 FY26 and operating margins at -89.06%. The negative financial trend, weak ROE of 4.10%, and absence of institutional support make this an unsuitable investment despite technical momentum. Wait for sustained fundamental improvement before considering entry.
For Existing Holders: Strongly consider exiting positions. The disconnect between technical strength (66.56% YTD gains) and fundamental deterioration (₹-32.54 crores consolidated loss in Q4 FY26) is unsustainable. The "Negative" financial trend, "Below Average" quality grade, and "Risky" valuation classification suggest the stock is priced for a turnaround that has not materialised. Use current price levels near ₹700 to exit and redeploy capital into fundamentally stronger opportunities.
Fair Value Estimate: ₹420-480 (40-45% downside risk from current levels of ₹699.80)
Riddhi Siddhi Gluco Biols' Q4 FY26 results expose deep-seated operational challenges that cannot be ignored. With revenue at multi-quarter lows, operating losses ballooning, and negative cash flow from operations, the company's fundamental health is severely compromised. While increased promoter holdings to 86.55% signal insider confidence, the absence of institutional investors, weak return metrics, and persistent capital inefficiency raise serious concerns. The stock's strong technical performance appears to be driven by retail speculation rather than underlying business strength, creating a dangerous trap for unsuspecting investors. Until the company demonstrates sustained revenue recovery, positive operating margins, and improved capital efficiency, the stock remains a high-risk proposition warranting a Strong Sell rating.
Note: ROCE = (EBIT - Other Income) / (Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Investments in equity markets carry inherent risks, including the potential loss of principal.
